secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-057186
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20
--------------------------------------------------------------------------------

- Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.
- Cash, cash equivalents, and restricted cash were $31.2M as of March 31, 2026; NIA grant funds $25.6M.
- FDA Division of Psychiatry meeting scheduled for May 20, 2026 to discuss registrational plans for zervimesine in DLB psychosis.
- Topline results from Phase 2 START study (COG0203) in early Alzheimer's expected in 2027.
- Presented two posters at AD/PD 2026 conference on zervimesine's effect and composite endpoint for DLB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/0001104659-26-057186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/tm2613845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer